ACI's 16th National Rx Drug Pricing Master Course

Topics

• Developing a Culture of Pricing Compliance - Strategies for Avoiding OIG and DOJ Scrutiny of Drug Pricing Practices
   

Mintz Levin's Bill Davis will speak on the panel, "Developing a Culture of Pricing Compliance - Strategies for Avoiding OIG and DOJ Scrutiny of Drug Pricing Practices," at ACI's 16th National Rx Drug Pricing Master Course.

Panel Description

• Understanding the current environment for compliance and enforcement related to pricing issues

• Identifying compliance guidance for pricing issues

• Anatomy of a government False Claims Act and Anti-Kickback investigations

• Identifying the roles of CMS, OIG and DOJ relative to pricing, rebates and enforcement

• Acknowledging the OIG’s direct pricing authority to determine and force WAMP (widely available market price) as an alternative to ASP

• Comprehending the OIG’s indirect impact on pricing

• Coupons

• Part D rebates and administrative fees

• Assessing potential anti-kickback violations with treatment of payment support programs for price reporting

• Bolstering compliance programs and internal practices to minimize the risk of investigations

• Analyzing enforcement trends

• False claims act cases
• Bundling cases

• Responding to government investigations

• Assessing the collateral consequences of investigations